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Abstract
Objective: Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-related 
death worldwide. The early diagnosis of colorectal tumors is one of the most important challenges in cancer 
management. MicroRNAs (miRNAs) have provided new insight into CRC development and have been suggested 
as reliable and stable biomarkers for diagnosis and prognosis. The aim of this study was to analyze the differential 
expression of miRNAs at different stages of CRC searching for possible correlation with clinicopathological 
features to examine their potential value as diagnostic biomarkers.      
Materials and Methods: In this case-control study, plasma and matched tissue samples were collected from 
74 CRC patients at stage II-IV as well as blood samples from 32 healthy controls. After exhaustive study of the 
current literature, eight miRNAs including miR-200c, 20a, 21, 31,135b, 133b,145 and let-7g were selected. The 
expression level of the miRNAs was assayed by quantitative reverse transcriptase-polymerase chain reaction 
(qRT-PCR). Statistical analysis, including t test , Mann-Whitney U, Kruskall-Wallis tests and receiver operating 
characteristic (ROC) curve was applied, where needed.
Results: Significantly elevated levels of miR-21, miR-31, miR-20a, miR-135b, and decreased levels of miR-
200c, miR-145 and let-7 g were detected in both plasma and matched tissue samples compared to the healthy 
group (P<0.05). However, no significant differences were observed in the expression level of plasma and tissue 
miR-133b (P>0.05). ROC for tissue miRNAs showed an area under the ROC curve (AUC) of 0.98 and P<0.001 
for miR-21, 0.91 and P<0.001 for miR-135b, 0.91 and P<0.001 for miR-31, and 0.92 and P<0.001 for miR-20a.     
Conclusion: Our results indicate that the expression levels of microRNAs are systematically altered in CRC tissue 
and plasma. In conclusion, detection of miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful 
to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers 
for diagnosis.           
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Introduction
Colorectal cancer (CRC) is one of the most commonly 
diagnosed types of cancer in men and women, 
worldwide. Each year, more than 1 million new cancer-
related cases are diagnosed, causing about 600,000 
deaths (1). Among Asian populations, both the incidence 
and mortality rates of CRC are increasing rapidly (2, 3). 
CRC is a complex disease, charactrized by anumber of 
genetic alterations and dysregulated signaling pathways 
(1). Since this malignancy is mainly asymptomatic and 
often diagnosed at the late stage with poor prognosis, 
a great emphasis is placed on early tumor detection to 
decrease the mortality rate (4). 
Colonoscopy is currently the gold standard and has very 
high sensitivity and specificity in detecting colorectal 
lesions, but because of its invasive nature and other 
limitations, is not considered as the best method of choice. 
Therefore, there is an urgent need for identifying stable, 
specific and reliable biomarkers to facilitate the early 
detection of CRC (5).
MicroRNAs (miRNAs), as well-known non-coding 
RNAs, have been demonstrated to be involvedin cancer 
development and progression. The major mechanisms 
of actions of most miRNAs involves translational 
inhibition and mRNA degradation, which is mediated 
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by complementary binding to target mRNAs (6, 7). 
Studies have indicated that miRNAs can control 
hundreds of target genes via their oncogenic or tumor-
suppressive activities depend on the target (6). 
Since their discovery, microRNAs have been found 
to regulate cellular processes which have key roles 
in different aspects of cancer biology, such as cell 
proliferation, apoptosis and differentiation (6, 7). 
Therefore, these molecules have recently achieved 
remarkable success in cancer management through 
their regulatory roles in gene expression and protein 
translation (8). There is increasing evidences that 
miRNAs are largely dysregulated in different types 
of solid cancerous tissues and their tissue-specific 
expression profiles have promising applications in 
cancer diagnosis, prognosis and treatment (9). 
Based on this background, identification of the 
altered miRNAs expression profiles as well as their 
association with tumorigenesis are important steps 
in cancer management (9, 10). On the other hand, 
it has been distinguished that the altered expression 
of miRNAs in a range of malignant tissues could be 
reflected in circulation, suggesting them as promising 
diagnostic biomarkers (10-12). A number of studies 
have also confirmed the potential value of circulating 
miRNAs as diagnostic and prognostic biomarkers for 
CRC (11, 12). However, to gain an insight into the 
role of miRNAs in CRC carcinogenesis, identifying 
their association with clinicopathological features is 
especially helpful (13). 
In this study, eight miRNAs (miR-21, miR-135b, 
miR-133, miR-let7-g, miR-31, miR-20a, miR-200c 
and miR-145) were particularly chosen based on 
comprehensive review of the literature and other 
previously published data on CRC. MiR-21, miR-
135b, miR-20a and miR-31 have been suggested as 
oncogenic regulators in CRC, whilst, let7-g, miR-145 
and miR-133b act as tumor suppressors. 
These miRNAs were selected for their potentials 
as diagnostic biomarkers and probable biological 
significance in CRC (10, 14, 15). However, it has been 
reported that miR-200c could act as an oncogene or 
tumor suppressor in CRC depending on TNM stage 
(13, 15-17). The purpose of this study was to examine 
the differential expression of CRC-associated miRNAs 
in tissue and plasma from different stages of the 
disease to evaluate their clinical value as diagnostic 
biomarkers. 
Materials and Methods
In this case-control study, a total of 74 blood samples 
(39 with stage II, 30 with stage III and 5 with stage 
IV of CRC) and a subset of 74 matched tumor tissues 
were collected from CRC patients. Histopathological 
features were confirmed by pathological analysis and 
the patients were staged according to the tumor-node-
metastasis (TNM) staging system of the International 
Union Against Cancer (16). 
This study has been approved in Ethic Committee of Iran 
University of Medical Sciences (Ethical code: IR.IUMS.
REC 1394.26649). Written and signed informed consent 
forms were gathered from all the volunteers participating 
in this study. Participation of individuals was voluntary 
and all participants were aware of the project’s purpose. 
The patients had received no chemotherapy. Also, all 
participants stated they had received no treatment in 
the two months prior to the study. In the healthy group, 
32 blood samples were collected from subjects with no 
current malignancy or infectious disease. The healthy 
subjects were matched to the cancer patients, according 
to age and gender. 
Sample collection and preparation 
The surgical tumor samples were microscopically 
inspected by an oncologist, who obtained a biopsy from 
a section representative of the colon or rectum tumor. 
The tumor tissue specimens were placed directly in 
RNALater (Thermo Fisher scientific, Germany) and 
transferred to the molecular laboratory and stored 
at -20˚C until use. Peripheral blood was collected in 
vacutainer liquid EDTA 6 ml blood collection tubes, 
and peripheral blood mononuclear cells (PBMCs) 
Cs and plasma fractions were separated by density 
gradient separation. Then, the upper layer (plasma) 
was stored in 2 ml DNase/RNase free microtubes and 
frozen at -80˚C until miRNA extraction. 
miRNA extraction
The plasma (200 µl) and tumor tissue (5 mg) samples 
were subjected to miRNA extraction. Frozen plasma 
samples were thawed and miRNAs were extracted 
using a miRNA extraction kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s instructions. 
Tissue miRNAs (tumor and the corresponding 
normal tissues) were isolated by a modified TRIzol 
protocol as explained previously (14). The quantity 
and quality of the extracted RNA was evaluated 
using spectrophotometry and gel electrophoresis, 
respectively.
cDNA synthesis
Total RNA (1 µg) was reverse transcribed into cDNA 
using cDNA Reverse Transcription Kit (Ampliqon, 
Denmark) as explained previously (16, 17). Briefly, 
1 μg of RNA was mixed with 1 μl of random hexamer 
primers and 1 μl M-MuLVreverse transcriptase (200 U/
μl). Nuclease-free diethyl pyrocarbonate (DEPC)-treated 
water was added to bring the mixture up to a volume of 15 
μl. Then, the mixture was incubated at 65˚C for 5 minutes 
in a 7500 thermocycler (ABI) and cDNA was synthesized 
with the program of 5 minutes at 25˚C, 60 minutes at 
42˚C, and 5 minutes at 70˚C.
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Bioinformatics study and miRNA selection
Eight miRNAs selected by virtue of being demonstrated 
as colorectal cancer-associated miRNAs and established as 
a tumor suppressors or an oncogenes in CRC. The miRNAs 
involved in colon cancer, were selected from the Sanger 
Center miRNA Registry at http://www.sanger.ac.uk/Software/
Rfam/mirna/index.shtml. Furthermore, we used some miRNA 
databases (miRDB, TargetScan, miRBase and miRTarBase) 
to predict the biological targets of miRNAs and validate 
microRNA-target interactions both in vitro and in vivo.
 Quantitative reverse transcriptase polymerase chain
reaction for detecting mature miRNAs
The expression of a for ementioned miRNAs was 
measured by a poly A quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) technique using 
specific oligonucleotide primers (14). All PCR reactions 
for CRC and control samples were performed in duplicate 
and the mean CT data was obtained using cycle threshold 
settings. The relative expression levels of miRNAs in 
tissue and plasma were normalized to that of RNU6B 
asaninternal control. The normalization was completed by 
using the equation: log
10
 (2−ΔΔCt), in which ΔΔCt =Ct
CRC
-
Ctcontrol (18).
Statistical analysis
At first, the normality of the data was assessed using 
the Kolmogorov-Smirnov test. Data were analyzed 
using the independent t test, when the distribution was 
normal, and Mann-Whitney U test, when the distribution 
was not normal. To evaluate the diagnostic value of the 
miRNAs, receiver operating characteristics (ROC) curve 
was completed. Level of significance for statistical tests 
was 0.05. The SPSS software version 22 was used for the 
analyses.
Results
 Clinicopathological characteristics of the studied
colorectal cancer patients
Clinicopathological features of the CRC patients have 
been detailed. There was no evidence of further disease 
complications in the participants. Conerning location of 
the tumors, 47 (63.5%) patients had rectum tumors, and 
27 (36.5%) located in the colon. Moreover, 39 participants 
(52.7%) had stage II, 30 (40.5%) had stage III, while 5 
(6.7%) had a stage IV CRC. The patients included 48 males 
(64.86%) and 26 females (35.13%) with ages rangingfrom 
29 to 84 years old (median age: 49.6 years). The clinical and 
pathological characteristics have been described (Table 1). 
Plasma miRNAs levels
The results demonstrated that all studied miRNAs (miR-
200c, miR-145, miR-135b, miR-133b, miR-31, miR-21, and 
miR-20a and let-7 g) were differentially expressed either 
in plasma or tissue samples from CRC patients compared 
to healthy controls. Based on the Kolmogorov-Smirnov 
test, these miRNA values were not normally distributed 
(P<0.05). Therefore, the Mann-Whitney U test was used 
to compare the expression of miRNAs between the CRC 
patients and controls. However, independent t test was 
applied to compare the expression of miRNAs between 
the CRC patients and controls. qPCR data indicated that 
the expression levels of plasma miR-20a, miR-21, miR-
31, miR-135b were significantly higher than those in the 
healthy controls (P<0.05, Figs. 1, 2). By contrast, the 
expression levels of miR-145, miR-let-7g and miR-200c 
were significantly lower (P<0.05) in the plasma of CRC 
patients than that of the healthy controls (P<0.05, Fig.3).
Table 1: Clinicopathological features of the studied CRC patients
Variable Number of RNA samples 
n=74
Age (Y)
   ≥55
   <55
33
41
Gender
   Male
   Female
48
26
TNM stage
   II
   III
   IV
39
30
5
Tumor size
   <2 cm
   2-3.5 cm
   3.5-5 cm
   >5 cm
10
31
24
9
Localization
   Colon
   Rectum
27
47
LVI
   Positive
   Negative
46
28
Differentiation
   Well Adeno
   Moderate Adeno
   Poor Adeno
11
59
4
CRC; Colorectal cancer, TNM; Tumor-node-metastasis, and LVI; Lympho 
vascular invasion.
Expression of miRNAs in colon cancer tissues
Based on the qPCR data, a statistically significant 
(P<0.001) up-regulation of miR-20a, miR-21, miR-31 
and miR-135b was found in the CRC tissues compared 
to normal adjacent mucosa. Conversely, the expression 
levels of miR-200c, miR-145 and let-7g were signific 
antly lower in tumor tissue compared to adjacent normal 
tissues (P<0.001, Figs.2, 4). However, no significant 
differences were found either in the expression level of 
plasma or tissue miR-133b between CRC patients and 
healthy controls (P>0.05). 
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Fig.1: The relative expression of miR-31, miR-200c, miR-20a, miR-135b, 
miR-133b, miR-21, miR-145 and let-7g in tissue [74 colorectal cancer (CRC) 
samples compared to 32 controls]. Lines in the middle show the mean 
expression value.
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Fig.2: The relative expression of miR-31, miR-200c, miR-20a, miR-135b, 
miR-133b, miR-21, miR-145 and let-7g in plasma [74 colorectal cancer 
(CRC) samples compared to 32 controls]. Lines in the middle show the 
mean expression value.
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Fig.3: Correlation of clinicopathologic features of colorectal cancer with the relative expression levels of miRNAs in plasma. A. Comparison of miRNA levels 
in colorectal cancer (CRC) and healthy controls, B. Comparison of miRNA expression level in patients with different tumor stages, C. Comparison of miRNA 
expression levels in different lymphovascular invasion (LVI) status, D. Comparison of miRNA expression levels in CRC according to age, E. Comparison of 
miRNA levels in CRC with different tumor sizes, F. Comparison of miRNA expression levels in colon and rectal cancers, G. Comparison of miRNA expression 
levels in patients with various tumor differentiation, and H. Comparison of miRNA expression levels in CRC based on patient’s gender.
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Fig.4: Correlation of clinicopathological features of colorectal cancer (CRC) with the tissue expression level of miRNAs. A. Comparison of miRNA expression 
levels in CRC and healthy controls, B. Comparison of miRNA expression levels in patients with various tumor stages, C. Comparison of miRNA expression 
levels in CRC in different lymphovascular invasion (LVI) status, D. Comparison of miRNA expression level in CRC according to patient’s age, E. Comparison 
of miRNA expression level in CRC with different tumorsizes, F. Comparison of miRNA expression levels in colon and rectal cancers, G. Comparison of miRNA 
expression levels in patients with different tumor differentiation, and H. Comparison of miRNA expressionlevels in CRC based on patient’s gender.
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 The correlation of miRNA expression between
matched tissue and plasma samples
Investigation of miRNA expression levels in tissue 
and matched plasma samples showed that the relative 
trends of miRNA expression are similar in both tissue and 
plasma samples. The correlation analysis of expression 
of selected miRNAs expression showed aimportant 
correlation of miRNA expression patterns in the tissues 
with those in the plasma, R2=0.831 (Fig.5). It suggested 
that plasma miRNA patterns accurately reflect the 
expression signature of their tissue counterparts. 
Fig.5: Evaluation of diagnostic power of miRNAs. A. Receiver operating 
characteristic (ROC) curve analysis using plasma, B. Tissue miRNAs expression 
levels for distinguishing colorectal cancer (CRC) samples (74 cancer samples 
and 32 healthy controls), and C. Pearson correlation scatter plot of miRNA 
expression levels in colorectal cancer tissue and plasma.
 Clinicopathologic features of colorectal cancer and
 miRNA expression
Further analysis wasperformed to examine whether 
there was an association between miRNA expression 
levels and different clinicopathologic features including 
tumor stages, age, gender, tumor size, differentiation and 
lymphovascular invasion (LVI) status. Characteristic 
stage-dependent variation in the expression level of tissue 
and plasma miRNAs were analyzed between various 
stages (II, III and IV) of CRC. The results showed miR-
21, miR-31, miR-20a, miR-135b were significantly 
upregulated in CRC (tumor stages II, III, IV) compared to 
normal colorectal tissues (P<0.05). In contrast, miR-145, 
let-7g and miR-200c were significantly downregulated 
in CRC (tumor stages II, III, IV)  compared to normal 
tissues (P<0.05).
The plasma levels of miR-21, miR-31, miR-20a and miR-
135b showed a significant rising with the higherstages of 
malignancy (P<0.05). By contrast, miR-145, miR-let-7g 
and miR-200c showed a significant decreasing trend with 
the higher stages of malignancy (P<0.05). Additionally, 
the plasma levels of let-7g showed a significant decrease 
in stage III compared to healthy control (P<0.05). 
The expression levels of miR-21, miR-31and miR-
135b in CRC plasma samples were significantly 
different between patients with stage II and III (P<0.05). 
Further analysis revealed no remarkable correlations 
between plasma and tissue levels of miRNAs and other 
clinicopathological features such as tumor size, tumor 
differentiation and LVI status ( Figs.3, 4).
Evaluation of the diagnostic power of miRNAs
To confirm the diagnostic value of the miRNAs 
signature, ROC curve analysis was performed for both the 
plasma and tissue data. The test demonstrated significant 
accuracy in discriminating CRC patients from healthy 
individuals for tissue miR-135b, miR-31, miR-21 and 
miR-20a. The calculating ROC AUC for tissue miRNAs 
was 0.98 and P<0.001 for miR-21, 0.91 and P<0.001 for 
miR-135b, 0.91 and P<0.001 for miR-31, and 0.92 and 
P<0.001 for miR-20a, which was suggestive of high 
discriminatory power (Fig.5).
Discussion
CRC is one of the deadliest malignancies that is 
frequently diagnosed at advanced stages with poor 
prognosis (1, 2). Therefore, there is an urgent need for 
finding stable and reliable biomarkers to facilitate early 
detection of the disease and decrease mortality rates (5, 
12). Micro RNAs (miRNAs), as a well-known group of 
non-coding RNAs, have been revealed to play a vital 
role in CRC carcinogenesis (7) . In addition, it has been 
suggested that CRC-associated miRNAs might serve 
as tissue-based biomarkers for cancer classification and 
diagnosis (6, 9). The circulating cell-free miRNAs have 
been regularly investigated in serum/plasma of cancer 
B
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patients and reported to bestable biomarkers in various 
malignancies including, CRC (5, 11). Nevertheless, 
various nucleic acids released from blood cells into serum 
during coagulation and the right spectrum of tumor-
derived circulating miRNAs fluctuates in serum samples. 
Since serum may potentially contain blood cell-derived 
miRNAs (15), we postulated the plasma samples can 
bemore reliable sources of tumor-derived circulating 
miRNAs.
Considering the oncogenic or suppressor roles designated 
for different miRNAs in cancer development (6, 9), it is 
valuable to identify CRC-related miRNA signatures to 
expand our knowledge of their biological function. Here, 
we investigated the pattern of plasma miRNA levels as well 
as matched tissue samples in CRC patients in comparison 
with healthy individuals and analyzed the potential value 
of these molecules as diagnostic biomarkers. In line with 
this aim, eight miRNAs (miR-21, miR-135b, miR-133, 
miR-let7-g, miR-31, miR-20a, miR-200c and miR-135b) 
were selected by virtue of having been demonstrated to be 
potential biomarkers for CRC (10, 13, 14). 
The expression analysis demonstrated that all studied 
miRNAs were differentially expressed in patients 
compared to healthy controls. Our results indicated the 
same altered expression pattern in both plasma and tissue 
samples. We observed significantly elevated levels of 
miR-21, miR-31, miR-20a and miR-135b and significantly 
decreased levels of miR-145, miR-200c and miR-let-7g in 
both plasma and matched tissue samples compared to the 
healthy groups. 
However, no significant differences were observed in the 
expression level of miR-133b either in plasma or tissue, 
between CRC patients and healthy controls. As well, 
the supplementary analysis demonstrated a significant 
correlation of miRNA expression levels in the CRC 
tissues and those in the plasma, with R2=0.831. These 
data illustrated that, the manner of miRNAs expression in 
plasma is similar to their corresponding tissues. 
A forementioned findings suggested that the plasma 
miRNA expression pattern in CRC could reflect the 
expression signature of the tumor tissue. It seems that, 
the CRC tumor-derived miRNAs could be release into the 
blood stream. Consistent with this, it has been confirmed 
that the epithelial tumor-derived miRNAs potentially 
enter into and can be detected in circulation. Furthermore, 
we evaluated the correlation between expression levels 
of the miRNAs and clinical features. The results clearly 
demonstrated that miRNAs exhibited some changes in 
their expression levels along with cancer development 
and progression.
Our finding showed that, miR-21 is significantly 
upregulated in both plasma and matched tissue of CRC 
samples compared to healthy controls. Also, a ROC curve 
(AUC) of 0.98 for tissue miR-21 was found. Further 
analysis revealed that, the expression level of miR-21 was 
significantly different between an earlier stage (II) versus 
the late stages (stages III, IV). MiR-21, as an oncogenic 
miRNA (oncomiR) regulates a number of important 
indications of the tumor-progressing process. 
Overexpression of miR-21 could enhance cell 
proliferation trough targeting PTEN and PI3K, 
whiledecreasing apoptosis via targeting BTG2, FasL and 
FBXO11. In addition, miR-21 has been shown to affect 
angiogenesis, metastasis, genetic instability and resistance 
to chemotherapy in several solid tumors including in CRC 
(19, 20).  In agreement with our results, the expression 
level of this miRNA has been reported to be associated 
with clinical stage and survival of CRC patients (20-22). 
Accordingly, a potential role of miR-21 in tumor growth 
and progression of the malignancy, and as a diagnostic 
biomarker was confirmed more than ever.
We also found that the expression of miR-135b both in 
tumor tissue or plasma was significantly up-regulated in 
comparison with that of healthy controls, which was in 
agreement with earlier studies (13, 22). MiR-135b, as an 
oncogenic regulator in CRC modulates cell proliferation, 
apoptosis and chemoresistance through regulating key 
tumor suppressor genes such as LATS1, LATS2 and APC 
(22). A number of studies have witnessed a remarkable 
upregulation of miR-135b in CRC tissues (13, 22) of 
mouse or human tumors, suggesting it as a primary event 
in CRC (8). 
Based on our results and pervious findings, miR-135b 
is believed to be involved in CRC development and 
progression (13, 22). However, tissue miR-135b with a 
specificity of 0.906 and a sensitivity of 0.973, and AUC 
of 0.91 showed a higher value than plasma miR-135b for 
cancer discrimination. 
Nevertheless, one study from the Chinese population, 
provided no evidences that circulating cell-free miR-
135b could be considered as a biomarker for early CRC 
detection (23). These inconsistent results may be due 
to the different approaches in sampling. Recent studies 
suggested that plasma, but not serum, is the sample 
of choice in examining cell-free circulating miRNAs, 
because miRNAs might be released from blood cells into 
serum during the coagulation process changing the true 
spectrum of circulating tumor-derived miRNAs (17). In 
this study plasma samples were chosen as a more reliable 
source of extracellular cancer-related miRNAs. 
In the present study, the upregulation of miR-31 in 
CRC tissue and plasma  samples in comparison with 
healthy subjects was revealed. In addition, we showed a 
significant upregulation of miR-31 in all clinical stages 
of CRC compared to healthy controls, which is supported 
by other studies (13, 24-27). Based on previous studies, 
miR-31 has been recognized as a potent cancer-related 
miRNA, involved in carcinogenesis of CRC by targeting 
tumor suppressor genes such as HIF-1α and CDKN2B 
(24, 25). This miRNA has also been demonstrated to act 
as an oncomiR in human CRC, where its overexpression 
is associated with cell proliferation, invasion and 
metastasis (13, 26). Our analysis, in line with the above-
mentioned studies, showed that tissue miR-31 with a 
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ROC AUC of 0.91 might serve as a potential diagnostic 
biomarker for CRC.
MiR-20a, as an upregulated miRNA in  CRC, has 
been revealed to increase cell migration and metastasis 
by suppressing Smad4 and E-cadherin expression (27, 
28). MiR-20a has also been shown to induce CRC cell 
proliferation trough suppression of the TGF-β signaling 
pathway and inhibition of the G1/S checkpoint (28). Our 
results are consistent with the previous studies (27, 28) 
showing a significant overexpression of miR-20a in CRC 
plasma and tumor compared to the healthy group. We also 
observed tissue miR-20a with a ROC AUC of 0.92 had a 
stronger power than plasma miR-20a for cancer diagnosis. 
Altogether, there was a positive association between high 
plasma and tissue expression of miR-20a and advanced 
clinical stages of CRC, suggesting a probable oncogenic 
role for miR-20a in the pathogenesis of CRC.
miR-200c, as a well-known post-transcriptional 
regulator in many cancer cell signaling pathways, is 
involved in tumor proliferation, cell cycle control, 
invasion, and metastasis (29, 30). Also, it has been 
reported that miR-200c could act as an oncogene or 
tumor suppressor in different types of cancers, or even at 
different stages of a defined tumor (30). We observed a 
significant downregulation of miR-200c in CRC samples 
compared to the healthy group. 
Our finding is not the first report of downregulation 
of miR-200c in CRC (31). Several functional studies 
have revealed that miR-200c inhibits epithelial-
mesenchymal transition (EMT) and cancer cell migration 
by downregulating ZEB1/2 and upregulating E-cadherins 
(31, 32). More recently, miR-200c has been shown 
to be downregulated at the invasive front of CRC 
while upregulated in the metastasis status (31). One 
rationalization for these findings may be the hyper- or 
hypomethylation trend of miR-200c through sequential 
steps of the tumor’s development (32). Notably, miR-200c 
expression levels were significantly lower in advanced 
stages (III and IV) than stage (II). These clinical findings 
supported the results from some related functional studies 
showing a downregulation of miR-200c in the initial 
stages of the disease (33). 
Let-7g, has been reported to target major oncogenes as 
a potent suppressor. Oncogenes including RAS, HMGA2, 
BCL2L1 and GAB2 that affect cell proliferation and 
apoptosis pathways (34). The significant downregulation 
of this molecule has been observed in numerous cancers, 
including lung, liver, breast, gastric and colon cancer (34, 
35). However, there are a few studies on the biological 
role of let-7g in the CRC (36). Our results exhibited 
significant reduced expression levels of let-7g in CRC 
compared to normal samples signifying this miRNA may 
act as a potential tumor-suppressor (37). Based on our 
findings and other investigations, this miRNA seems to 
be associated with clinical outcomes of colorectal cancer. 
MiR-145 can function as a suppressor of cell 
proliferation and tumor metastasis through targeting 
multiple oncogenes such as MYC, Kras, IRS-1, SOX2, 
MUC1, etc. (38, 39), and its expression level has been 
shown in several cancer cell lines (40). A number of 
previous studies reported a significantly reduced level 
of miR-145 at the adenomatous and clinical stages of 
colorectal neoplasm (21, 26). 
We found a significant reduction in the expression of 
miR-145 in cancer patients in comparison with healthy 
controls. Based on these findings, this miRNA may be 
associated with clinical outcome of colorectal cancer. 
Taken together, our results indicated that the expression 
levels of miRNAs are systematically altered in CRC tissue 
and plasma samples. Moreover, the aberrant regulations 
of miRNAs are relatedto different clinical stages of 
CRC. The predictable changes of miRNA signatures may 
happen during tumorigenesis and may be representative 
of CRC development. These evidences are helpful in 
illuminating the molecular mechanisms underlying CRC 
carcinogenesis. On the other hand, the combination of the 
miRNAs-based biomarkers with other existing screening 
tests could be useful for diagnostic and prognostic 
accuracy as well as therapeutic planings. 
Conclusion
Our results supported the hypothesis that plasma 
miRNAs expression pattern might reflect the expression 
pattern of their matched tissues. Our findings suggested 
that differential expression of miR-31, 20a and 135b 
and 21 may be serve as potential biomarkers for CRC 
detection.
Acknowledgements
The authors wish to thank the Deputy of Research, Iran 
University of Medical Sciences for financially supporting 
this study (Grant No. 26649). We also thank the patients 
who participated in the study. All authors declare that they 
have no competing conflicts of interests. 
Authors’ Contributions
S.E., A.A., M.H.; Contributed to study design and 
conception. S.E., H.G., S.A.; Contributed to the 
examinationand selection of patients, collected the 
samples. A.M., E.F.; Provided scientific advice. S.E.; 
Performed the experiments, prepared the manuscript 
which A.A., H.G., M.H. significantly revised. A.A., M.H.; 
Assisted with analysis of the data. All authors read and 
approved the final manuscript.
References
1. Akbari A, Agah S, Heidari M, Mobini GR, Faghihloo E, Sarveazad 
A, et al. Homeodomain protein transforming growth factor beta-
induced factor 2 like, X-linked function in colon adenocarcinoma 
cells. Asian Pac J Cancer Prev. 2017; (18): 2101-2108.
2. Akbari A, Mobini GR, Maghsoudi R, Akhtari J, Faghihloo E, Far-
ahnejad Z. Modulation of transforming growth factor-β signaling 
transducers in colon adenocarcinoma cells induced by staphylo-
coccal enterotoxin B. Mol Med Rep. 2016; 13(1): 909-914.
3. Akbari A, Amanpour S, Muhammadnejad S, Ghahremani MH, 
Ghaffari SH, Dehpour AR, et al. Evaluation of antitumor activity of a 
TGF-beta receptor I inhibitor (SD-208) on human colon adenocar-
Cell J, Vol 20, No 2, Jul-Sep (Summer) 2018 230
Eslamizadeh et al.
cinoma. Daru. 2014; 22(1): 47.
4. Mirzaei A, Madjd Z, Kadijani AA, Tavakoli-Yaraki M, Modarresi MH, 
Verdi J, et al. Evaluation of circulating cellular DCLK1 protein, as the 
most promising colorectal cancer stem cell marker, using immunoas-
say based methods. Cancer Biomark. 2016; 17(3): 301-311.
5. Mobini GR, Ghahremani MH, Amanpour S, Dehpour AR, Akbari A, 
Hoseiniharouni SM, et al. Transforming growth factor beta-induced 
factor 2-linked X (TGIF2LX) regulates two morphogenesis genes, Nir1 
and Nir2 in human colorectal. Acta Med Iran. 2016; 54(5): 302-307.
6. Flatmark K, Hoye E, Fromm B. MicroRNAs as cancer biomarkers. 
Scand J Clin Lab Invest Suppl. 2016; 245: S80-S83.
7. Fadakar P, Akbari A, Ghassemi F, Mobini GR, Mohebi M, Bolhas-
sani M, et al. Evaluation of SD-208, a TGF-β-RI kinase inhibitor, as 
an anticancer agent in retinoblastoma. Acta Med Iran. 2016; 54(6): 
352-358.
8. Faghihloo E, Akbari A, Adjaminezhad-Fard F, Mokhtari-Azad T. 
Transcriptional regulation of E-cadherin and oncoprotein E7 by val-
proic acid in HPV positive cell lines. Irani J  Basic Med Sci. 2016; 
19(6): 601- 607.
9. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in 
human solid tumors. Cancer Lett. 2013; 329(2): 125-136.
10. Asnafi AA, Khodadi E, Golchin N, Alghasi A, Tavakolifar Y, Saki N. 
Association between microRNA-21, microRNA-150, and micro-
RNA-451 expression and clinical outcome of patients with acute 
lymphoblastic leukemia. Frontt Biol. 2017; 12(1): 63-70.
11. Ferracin M, Lupini L, Mangolini A, Negrini M. Circulating non-coding 
RNA as biomarkers in colorectal cancer. Adv Exp Med Biol. 2016; 
937: 171-181.
12. Mirzaei A, Madjd Z, Amini Kadijani A, Alinaghi S, Akbari A, Ta-
voosidana G. Cancer Stem cell’s potential clinical implications. Iran 
J Cancer Manag. 2017; 10(1): e5897.
13. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, et al. Expres-
sion of miR-21, miR-31, miR-96 and miR-135b is correlated with 
the clinical parameters of colorectal cancer. Oncol Lett. 2012; 4(2): 
339-345.
14. Akbari A, Ghahremani MH, Mobini GR, Abastabar M, Akhtari J, Bol-
hassani M, et al. Down-regulation of miR-135b in colon adenocar-
cinoma induced by a TGF-β receptor I kinase inhibitor (SD-208). 
Iran J Basic Med Sci. 2015; 18(9): 856.
15. Mohebi M, Akbari A, Babaei N, Sadeghi A, Heidari M. Identification 
of a de novo 3bp deletion in CRYBA1/A3 gene in autosomal domi-
nant congenital cataract. Acta Med Iran. 2016; 54(12): 778-783.
16. Karimi A, Majidzadeh-A K, Madjd Z, Akbari A, Habibi L, Akrami 
SM, et al. Effect of copper sulfate on expression of endogenous L1 
retrotransposons in HepG2 cells (hepatocellular carcinoma). Biol 
Trace Elem Res. 2015; 165(2): 131-134.
17. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Com-
paring the MicroRNA spectrum between serum and plasma. PLoS 
One. 2012; 7(7): e41561.
18. Akbari A, Farahnejad Z, Akhtari J, Abastabar M, Mobini GR, Me-
hbod ASA. Staphylococcus aureus enterotoxin B down-regulates 
the expression of transforming growth factor-beta (TGF-β) signal-
ing transducers in human glioblastoma. Jundishapur J Microbiol. 
2016; 9: e27297.
19. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan 
J, et al. Plasma miR-21: a potential diagnostic marker of colorectal 
cancer. Ann Surg. 2012; 256(3): 544-551.
20. Xia X, Yang B, Zhai X, Liu X, Shen K, Wu Z, et al. Prognostic role 
of microRNA-21 in colorectal cancer: a meta-analysis. PLoS One. 
2013; 8(11): e80426.
21. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bed-
narikova M, et al. Altered expression of miR-21, miR-31, miR-143 
and miR-145 is related to clinicopathologic features of colorectal 
cancer. Oncology. 2008; 72(5-6): 397-402.
22. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock 
V, et al. MicroRNA-135b promotes cancer progression by acting 
as a downstream effector of oncogenic pathways in colon cancer. 
Cancer Cell. 2014; 25(4): 469-483.
23. Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula 
R, et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b 
in serum: evidence against their usage as biomarkers in colorectal 
cancer. Cancer Biomark. 2013;12(4): 199-204.
24. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, et al. MicroRNA-31 ac-
tivates the RAS pathway and functions as an oncogenic MicroRNA 
in human colorectal cancer by repressing RAS p21 GTPase acti-
vating protein 1 (RASA1). J Biol Chem. 2013; 288(13): 9508-9518.
25. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on 
TIAM1 to regulate migration and invasion of colon carcinoma cells. 
J Biol Chem. 2010; 285(46): 35293-35302.
26. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K. Clini-
cal relevance of microRNA miR-21, miR-31, miR-92a, miR-101, 
miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012; 
12: 505.
27. Zhang GJ, Li Y, Zhou H, Xiao HX, Zhou T. miR-20a is an independ-
ent prognostic factor in colorectal cancer and is involved in cell 
metastasis. Mol Med Rep. 2014; 10(1): 283-291.
28. Xu T, Jing C, Shi Y, Miao R, Peng L, Kong S, et al. MicroRNA-20a 
enhances the epithelial-to-mesenchymal transition of colorectal 
cancer cells by modulating matrix metalloproteinases. Exp Ther 
Med. 2015; 10(2): 683-688.
29. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in 
human cancer. Cancer Lett. 2014; 344(2): 166-173.
30. Kumar S, Nag A,  Mandal CC. A comprehensive review on miR-
200c, a promising cancer biomarker with therapeutic potential. 
Curr Drug Target. 2015; 16(12): 1381-1403.
31. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkie-
wicz A, Goodall GJ. Down-regulation of the miRNA-200 family at 
the invasive front of colorectal cancers with degraded basement 
membrane indicates EMT is involved in cancer progression. Neo-
plasia. 2013; 15(2): 180-191.
32. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, 
et al. MicroRNA-200c modulates epithelial-to-mesenchymal tran-
sition (EMT) in human colorectal cancer metastasis. Gut. 2013; 
62(9): 1315-1326.
33. Cristóbal I, Rincón R, Manso R, Caramés C, Aguilera O, Madoz-
Gurpide J, et al. Deregulation of miR-200b, miR-200c and miR-429 
indicates its potential relevant role in patients with colorectal can-
cer liver metastasis. J  Surg Oncol. 2014; 110(4): 484-485.
34. Torrisani J, Parmentier L, Buscail L, Cordelier P. Enjoy the silence: 
the story of let-7 microRNA and cancer. Curr Genomics. 2007; 8(4): 
229-233.
35. Agah S, Akbari A, Talebi A, Masoudi M, Sarveazad A, Mirzaei A, 
et al. Quantification of plasma cell-free circulating DNA at different 
stages of colorectal cancer. Cancer Invest. 2017; 35(10): 625-632.
36. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a poten-
tial growth suppressor in human colon cancer cells. Biol Pharma-
ceutical Bulletin. 2006; 29(5): 903-906.
37. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. 
Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associ-
ated with chemoresponse to S-1 in colon cancer. Cancer Genom-
ics-Proteomics. 2006; 3(5): 317-324.
38. Li S, Wu X, Xu Y, Wu S, Li Z, Chen R, et al. miR-145 suppresses 
colorectal cancer cell migration and invasion by targeting an ETS-
related gene. Oncol Report. 2016; 36(4): 1917-1926.
39. Khalili M, Sadeghizadeh M, Ali Mk, Malekzadeh R, Vasei M, Mowla 
Sj. Down-regulation of the genes involved in reprogramming (Oct4, 
Sox2, P21, Esc-Specific Microrna Mir-302 And Mir-145) in gastric 
adenocarcinoma. J Gastrointest Cancer. 2015; 46(3): 251-258. 
40. Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour sup-
pressor that regulates multiple cellular pathways. J Cell mol Med. 
2014; 18(10): 1913-1926.
